Nagaland News Today

Anti-GBM Disease market size in the 7MM is expected to rise by 2030 with a CAGR of 22.2% during the study period (2018-2030), Estimates DelveInsight

Anti-GBM Disease market size in the 7MM is expected to rise by 2030 with a CAGR of 22.2% during the study period (2018-2030), Estimates DelveInsight

May 02
20:04 2022
Anti-GBM Disease market size in the 7MM is expected to rise by 2030 with a CAGR of 22.2% during the study period (2018-2030), Estimates DelveInsight
Anti-GBM Disease market

Anti-Glomerular Basement Membrane (anti-GBM) disease (also known as Goodpasture syndrome or disease) is a rare but serious autoimmune disease that causes inflammation in the kidneys and lungs. Anti-GBM disease may affect only the kidneys; however, when it causes both kidney and lung disease, it is called Goodpasture’s syndrome. In anti-GBM disease, the immune system mistakenly makes “anti-GBM antibodies” that attack the lungs and kidneys, leading to bleeding and inflammation in the organs.

 

DelveInsight’s ‘Anti-GBM Disease Market Insights, Epidemiology, and Market Forecast 2030’ report delivers an in-depth understanding of the Anti-GBM disease, historical and forecasted epidemiology as well as the Anti-GBM Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

Some facts of Anti-GBM Disease Market are:

  • Delveinsight Estimates that the highest cases of Anti-GBM Disease in the 7MM were in United States, followed by the Germany, France, the United Kingdom, Italy, Spain, and Japan in 2020.
  • According to DelveInsight, In the United States, the total number of incident cases of Anti-GBM Disease was 532 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.
  • According to DelveInsight, In the year 2020, the total incident cases of Anti-GBM Disease were 522 cases in EU-5 which are expected to grow during the study period, i.e., 2018–2030.
  • According to DelveInsight, In Japan, the total number of incident cases of Anti-GBM Disease was 63 cases in the year 2020 which are expected to grow during the study period, i.e., 2018–2030.

 

To get detailed analysis of Anti-GBM Disease Market Report, Click Here @ https://www.delveinsight.com/sample-request/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights

 

Scope of the Anti-GBM Disease Market Report

  • The report covers the descriptive overview of Anti-GBM, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Anti-GBM epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Anti-GBM is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Anti-GBM market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anti-GBM market.

 

Anti-GBM Disease Pipeline Drugs and Companies:

  • Idefirix (Imlifidase/HMed-IdeS): Hansa Biopharma
  • And Others

  

Expert Analysis:

  • Increase in the geriatric population play an important role in the development and exacerbation of Anti-GBM therapeutics market. Due to the growing pace of the elder population, the market of Anti-GBM is expected to increase in the forecast period.
  • Despite having lots of diagnosis options there are high chances of patients getting delay in diagnosis for Anti-GBM can be observed and the possible hurdles might be the lack of proper understanding of the disease (Anti-GBM).
  • Among the emerging therapies, Hansa Biopharma’s Idefirix (Imlifidase/HMed-IdeS), appears to be the only drug which have the potential to transform the Anti-GBM Disease market owing to impressive clinical data.

 

To get detailed analysis of Anti-GBM Disease Market Report, Click Here @ https://www.delveinsight.com/sample-request/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights

 

Table of Contents:

1. Key Insights

2. Report Introduction

3. Anti-Glomerular Basement Membrane (anti-GBM) Disease Market Overview at a Glance

4. Executive Summary of Anti-Glomerular Basement Membrane (Anti-GBM) Disease

5. Epidemiology and Market Methodology

6. Disease Background and Overview

7. Diagnosis of Anti-GBM disease

8. Diagnostic Guidelines

9. Treatment of Anti-GBM disease

10. Treatment Guidelines

11. Epidemiology and Patient Population

12. Patient Journey Anti-GBM

13. Key Endpoints in Anti-GBM Disease Clinical Trials

14. Emerging Therapies

14.1. Idefirix (Imlifidase/HMed-IdeS): Hansa Biopharma

15. Anti-GBM Disease: 7 Major Market Analysis

16. Market Access and Reimbursement

17. KOL Views

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Unmet Needs

22. Appendix

23. DelveInsight Capabilities

24. Disclaimer

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights

About Author

admin

admin